|
|
Article: Nabi Biopharmaceuticals Signs Definitive Agreement to Sell PhosLo(R) to Fresenius Medical Care.
- Article from:
- PR Newswire
- Article date:
- October 12, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Nabi Biopharmaceuticals' Cash Position Enhanced -
- Company's Core Strategic Goal of Optimizing Value from Operations Furthered -
- Company to Hold Conference Call on October 12, 2006 at 9:30 AM, EDT -
BOCA RATON, Fla., Oct. 12 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals announced today that it has signed a definitive agreement to sell PhosLo(R) (calcium acetate) and the product's related assets to a US subsidiary of Fresenius Medical Care ("Fresenius") for consideration of up to $150 million in up front cash, milestone payments, and royalties on sales of a new product formulation under development.
Under the terms of the ...